CD8A and non-small cell lung carcinoma: conducted a retrospective study in patients with advanced non-small cell lung cancer (NSCLC) receiving anti-PD-1 therapy and developed two nomograms incorporating absolute counts of CD3+, CD4+, CD8+, and B cells.